RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in bulk and Pharmaceutical Dosage form  and its stability studies

Authors

  • Bavita Gaur Faculty of Pharmacy, RKDF University, Bhopal, Madhya Pradesh, India
  • Sandeep Sahu Faculty of Pharmacy, RKDF University, Bhopal, Madhya Pradesh, India
  • Mohan Lal Kori Faculty of Pharmacy, RKDF University, Bhopal, Madhya Pradesh, India

DOI:

https://doi.org/10.25004/IJPSDR.2024.160318

Abstract

The present study shows an easy, quick, and reliable reverse-phase high-performance liquid chromatography method for measuring both erlotinib and ramucirumab. For the separation and quantification, an Inertsil column (150 × 4.6 mm, 3.5 μ) is used and a mobile phase comprising acetonitrile and 0.1% formic acid (50:50) combination was utilized. A UV detector was used to locate the eluents at 236 nm, and the flow rate was 1.0 mL/min. The retention times were found to be 2.936 and 4.535 minutes, respectively. The suggested approach was validated in accordance with ICH guidelines Q2 (R1), and it was found that the linearity of the findings fell between 2.50 and 15.00 μg/mL for ramucirumab and between 37.50 and 225.00 μg/mL for erlotinib. Erlotinib and ramucirumab demonstrated recovery rates of 99.6 and 100.1%, respectively. The robustness, accuracy, precision, and linearity range of the proposed method were all validated.

Downloads

Download data is not yet available.

References

Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002 Sep;3(9):1385-95.

Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 2003 Jan;12(1):51-64.

Delbaldo C, Faivre S, Raymond E. Epidermal growth factor inhibitors. Rev Med Interne. 2003 Jun;24(6):372-83.

Bulgaru AM, Mani S, Goel S, Perez-Soler R. Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther. 2003 Jun;3(3):269-79.

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R. FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600. Epub 2015 Jun 5.

Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014 Oct 29; 7:1997-2006. doi: 10.2147/OTT.S61132. eCollection 2014.

Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014 Dec 1;20(23):5875-81. doi: 10.1158/1078-0432.CCR-14-1071. Epub 2014 Oct 3.

Jyothi SD, Raju GE, Maheswari KU, Raghava D, Rao KN. Analytical Method Development and Validation for the Simultaneous Estimation of Ramucirumab and Paclitaxel by RP-HPLC Technique. Int. J. Pharm. Natural Med. 2023; 11(1): 52-58.

Chaitanya SM, Nissankararao S, Gandham SL. A New Np-UPLC Method for The Separation and Simultaneous Quantification of Ramucirumab and Erlotinib. International Journal of Applied Pharmaceutics 2021; 13(6): 75–81. https://doi.org/10.22159/ijap.2021v13i6.42815

Amirtharaj RV, Lavanya S. Development and validation of RP-HPLC and UV method for Erlotinib hydrochloride tablets. IP Int J Compr Adv Pharmacol 2021;6(3):144-151.

van Veelen A, van Geel R, Schoufs R, de Beer Y, Stolk LM, Hendriks LEL, Croes S. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomed Chromatogr. 2021 Dec;35(12):e5224. doi: 10.1002/bmc.5224. Epub 2021 Aug 31. PMID: 34363425.

Latha ST, Thangadurai SA, Jambulingam M, Sereya K, Kamalakannan D, Anilkumar M. Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation, Arabian Journal of Chemistry 2017; 10(1):S1138-S1144. https://doi.org/10.1016/j.arabjc.2013.02.006

Bolandnazar S, Divsalar A, Valizadeh H, Khodaei A, Zakeri-Milani P. Development and application of an HPLC method for Erlotinib protein binding studies. Adv Pharm Bull. 2013;3(2):289-93. doi: 10.5681/apb.2013.047. Epub 2013 Aug 20. PMID: 24312850; PMCID: PMC3848207.

Chakravarthy VK, Gowri Sankar D. Development and validation of RP-HPLC method for estimation of Erlotinib in bulk and its pharmaceutical formulation. Rasayan J. Chem. 2011; 4(2): 393-399.

U.S. Food and Drug Administration. Guidance for Industry, Analytical Procedures and Methods Validation for Drugs and Biologics; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2015.

International conference on the harmonization. ICH Harmonized Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005.

United States Pharmacopoeia. <1225> Validation of Compendial Procedures; USP32–NF27; The United States Pharmacopeial Convention: Rockville, MD, USA, 2007; Volume 34, p. 794.

International conference on the harmonization. ICH Harmonized Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A (R2), November 2003.

International conference on the harmonization. ICH Harmonized Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005.

Downloads

Published

30-05-2024

Issue

Section

Research Article

How to Cite

“RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in Bulk and Pharmaceutical Dosage Form  and Its Stability Studies”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 16, no. 3, May 2024, pp. 452-7, https://doi.org/10.25004/IJPSDR.2024.160318.